Shopping Cart
- Remove All
Your shopping cart is currently empty
Foralumab (NI-0401) is an orally available human anti-CD3 monoclonal antibody that downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells from COVID-19 subjects for the study of COVID-19 infection.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $169 | In Stock | |
| 5 mg | $428 | In Stock | |
| 10 mg | $689 | In Stock | |
| 25 mg | $1,050 | In Stock | |
| 50 mg | $1,420 | In Stock |
| Description | Foralumab (NI-0401) is an orally available human anti-CD3 monoclonal antibody that downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells from COVID-19 subjects for the study of COVID-19 infection. |
| In vivo | Foralumab (0.6-250 μg; oral; once daily for 5 days) showed delayed rejection in B6Rag2 skin grafts transplanted into humanized mice. [1] Foralumab (0.6-250 μg; oral and inhalation; once daily for 5 days) inhibits rejection of cutaneous xenografts in mice with human immune systems. [1] Foralumab (1-15 μg; oral; once daily for 5 days) demonstrated good bioavailability in humanized mice following intragastric administration. [1] |
| Synonyms | NI-0401, NI0401 |
| Cas No. | 946415-64-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.